Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX) jumped 6.8% in the afternoon session after the company reported strong fourth-quarter financial results and offered an upbeat ...

Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript February 10, 2026 Quest Diagnostics Incorporated ...

DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and ...

Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.35. Anticipation surrounds Quest ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Jim Davis, Quest Diagnostics CEO, discusses how chronic disease management and consumer health testing are driving growth in ...

The Quest Diagnostics patient service center at 1 Randall Square reopened last week following renovations. Quest leaders ...

Quest Diagnostics (DGX) stock hits a 52-week high as the company beats estimates with its Q4 2025 financials and set its 2026 ...

Shares of Quest Diagnostics rose after the company's full-year outlook and quarterly results topped Wall Street's expectations. The stock was up 4.9% to $200.53 in midday trading on Tuesday. Earlier ...